Evgenios Goussetis
Overview
Explore the profile of Evgenios Goussetis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
406
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paisiou A, OIkonomopoulou C, Pavlidis D, Ampatzidou M, Komitopoulou A, Ioannidou E, et al.
Leuk Lymphoma
. 2024 Dec;
66(3):557-560.
PMID: 39616627
No abstract available.
2.
Kalwak K, Moser L, Potschger U, Bader P, Kleinschmidt K, Meisel R, et al.
Blood Adv
. 2024 Nov;
9(4):741-751.
PMID: 39602342
The superiority of total body irradiation (TBI)-based vs chemotherapy conditioning for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children with acute lymphoblastic leukemia (ALL) has been established in the international,...
3.
Tragiannidis A, Antari V, Tsotridou E, Sidiropoulos T, Kaisari A, Palabougiouki M, et al.
Hematol Rep
. 2024 Oct;
16(4):579-584.
PMID: 39449299
Despite the progress achieved regarding survival rates in childhood acute lymphoblastic leukemia (ALL), relapsed or refractory disease still poses a therapeutic challenge. Inotuzumab ozogamicin is a CD22-directed monoclonal antibody conjugated...
4.
Konteles V, Papathanasiou I, Tzetis M, Goussetis E, Trachana V, Mourmoura E, et al.
Cells
. 2023 Jul;
12(13).
PMID: 37443790
Although MSCs grant pronounced potential for cell therapies, several factors, such as their heterogeneity restrict their use. To overcome these limitations, iMSCs (MSCs derived from induced pluripotent stem cells (iPSCs)...
5.
Neroutsos E, Nalda-Molina R, Paisiou A, Zisaki K, Goussetis E, Spyridonidis A, et al.
Pharmaceutics
. 2022 Mar;
14(3).
PMID: 35336021
We develop a population pharmacokinetic model to describe Busulfan pharmacokinetics in paediatric patients and investigate by simulations the impact of various sampling schedules on the calculation of AUC. Seventy-six children...
6.
OIkonomopoulou C, Paisiou A, Ioannidou E, Komitopoulou A, Kaisari A, Zisaki K, et al.
Pediatr Transplant
. 2022 Feb;
26(4):e14239.
PMID: 35122456
Background: Infants are subjected to hematopoietic stem cell transplantation (HSCT) due to malignant and non-malignant diseases. However, specific data concerning the outcome and transplantation-related complications in infants, as a separate...
7.
OIkonomopoulou C, Goussetis E
Bone Marrow Transplant
. 2021 Sep;
56(12):2882-2888.
PMID: 34531544
Patients with β-thalassemia suffer from severe anemia, iron overload and multiple complications, that affect their quality of life and well-being. Allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA-matched sibling...
8.
Komitopoulou A, Paisiou A, OIkonomopoulou C, Kaisari K, Ioannidou E, Tzannou I, et al.
J Pediatr Hematol Oncol
. 2021 Mar;
44(2):e456-e459.
PMID: 33710116
Carbapenem resistance, most notably in Klebsiella pneumonia (KPC), results in infections associated with significant morbidity and mortality. Here we report 2 cases of adolescent patients with KPC infection after high-risk...
9.
OIkonomopoulou C, Paisiou A, Komitopoulou A, Ioannidou E, Kaisari A, Tzannou I, et al.
Br J Haematol
. 2021 Feb;
192(5):e127-e129.
PMID: 33522599
No abstract available.
10.
Sfougataki I, Varela I, Stefanaki K, Karagiannidou A, Roubelakis M, Kalodimou V, et al.
Histol Histopathol
. 2020 Sep;
35(12):1415-1426.
PMID: 32959885
Introduction: Mesenchymal stromal cells (MSCs) can be derived from a wide range of fetal and adult sources including pluripotent stem cells (PSCs). The properties of PSC-derived MSCs need to be...